Market Capitalization

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

With a key drug decision looming and a refocused strategy, Rocket Pharmaceuticals faces a critical audience at the J.P. Morgan Healthcare Conference.

Solmate Infrastructure appoints financial heavyweight Erez Simha to its board, bolstering its ambitious plan to build a Solana hub in Abu Dhabi.

Occidental nets $9.7B from its OxyChem sale to Berkshire Hathaway, pivoting to oil and carbon capture while retaining significant environmental liabilities.

China's JIADE LIMITED partners with South Korea's Chinalink, leveraging AI to expand education services to North America, Asia, and the Middle East.

Fresh off a major drug approval, Insmed's upcoming J.P. Morgan talk is under scrutiny as investors eye pipeline updates and acquisition potential.

Following the sale of its legacy business, the newly-rebranded Accendra Health launches on the NYSE with a laser focus on the booming home healthcare market.

Viomi Technology's $20M share repurchase program underscores faith in its 'Global Water' strategy, even as its stock faces a volatile market.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

Just months after its IPO, Kandal M Venture is fighting to stay on Nasdaq. We explore the financial woes behind the stock's dramatic fall.

As Northern Trust prepares its Q4 2025 earnings call, investors seek clues on its resilience amid shifting economic tides and strategic digital pivots.

The semiconductor equipment firm will release crucial 2025 and 2026 financial guidance in January, offering a key early test of the industry's momentum.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

Mixed Martial Arts Group lands $3 million in funding, with Donald Trump Jr. investing, to fuel its ambitious blockchain-based fan engagement platform.

With a new HQ and $2M in contracts, Taoping is leveraging AI and government policy to modernize China's aging elevators, but faces investor scrutiny.

Eightco Holdings bets big on its own stock with a $125M buyback, banking on its Worldcoin treasury and a vision for AI-proof digital identity.

Chegg repurchases convertible notes at a discount, a calculated move to strengthen its finances as it pivots to the competitive skilling market.

Facing soaring demand, AI robotics firm TechForce is seeking a global manufacturing partner, signaling a major shift from pilot programs to mass production.